Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BCL10
REST API REST API
Homo sapiens
BCL10 is differentially expressed in 253 experiments: 111 organism parts: lung, esophagus, ... (109 more);, 164 disease states: normal, glioblastoma, ... (162 more);, 71 cell types 282 cell lines 37 compound treatments and 60 other conditions.
Synonyms c-E10, CARMEN, CLAP, CIPER, mE10
Orthologs Bcl10 (Mus musculus)   BCL10 (Gallus gallus)   Q17QJ6_BOVIN (Bos taurus)   Bcl10 (Rattus norvegicus)   bcl10 (Xenopus laevis)   BCL10 (Danio rerio)   BCL10 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, cytoplasm, intracellular, innate immune response, protein complex, membrane, response to chemical stimulus, lysosome, protein homooligomerization, kinase binding, positive regulation of protein ubiquitination, membrane raft, transcription factor binding, I-kappaB kinase/NF-kappaB cascade, protein oligomerization, induction of apoptosis, transcription coactivator activity, protein kinase binding, protein self-association, nucleus, cell death, perinuclear region of cytoplasm, positive regulation of NF-kappaB transcription factor activity, protein C-terminus binding, ubiquitin binding, cellular defense response, enzyme binding, response to fungus, positive regulation of transcription, DNA-dependent, regulation of apoptosis, ubiquitin protein ligase binding, protease binding, positive regulation of I-kappaB kinase/NF-kappaB cascade, lymphotoxin A biosynthetic process, T cell receptor signaling pathway, positive regulation of T cell activation, neural tube closure, immunological synapse, toll-like receptor signaling pathway, lipopolysaccharide receptor complex, cellular response to mechanical stimulus, positive regulation of mast cell cytokine production, positive regulation of phosphorylation, negative regulation of mature B cell apoptosis, NF-kappaB binding, response to molecule of bacterial origin, kinase activator activity, regulation of T cell receptor signaling pathway, protein kinase B binding, interleukin-6 biosynthetic process, adaptive immune response, T cell receptor complex, positive regulation of interleukin-8 biosynthetic process, immunoglobulin mediated immune response, CBM complex
InterPro Term CARD
UniProt Accession O95999, Q5VUF1
Gene-Disease Assocation COLORECTAL CANCER; CRC
Search EB-eye ENSG00000142867
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-MTAB-62, E-GEOD-3202, ... (27 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
U251
2
E-GEOD-20089, E-MTAB-62
SKMEL3
1
E-MTAB-37
PC9
1
E-MTAB-62
276 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (37 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
whole blood
2
E-GEOD-3026, E-MTAB-25
cardiac myocyte
1
E-AFMX-5
skin substitute
1
E-GEOD-3204
mononuclear
1
E-GEOD-13987
65 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-GEOD-5370, ... (51 experiments)

Factor Value U/D Experiments
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
3
E-GEOD-4290, E-MTAB-62, E-GEOD-6014, E-GEOD-4412, E-MEXP-567 ... (5 experiments)
B-precursor acute lymphoblastic leukemia
1
E-GEOD-1577
hepatocellular carcinoma
1
E-MTAB-37
Ischemia
1
E-MTAB-62
158 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-1417, E-TABM-782, E-MEXP-941, ... (23 experiments)

Factor Value U/D Experiments
ponasterone A
1
E-GEOD-3113
phenol
1
E-GEOD-6907
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
camptothecin
1
E-GEOD-1417
Cxcl12
1
E-GEOD-7307
placebo
1
E-MEXP-1335
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-MTAB-37, E-MEXP-1251, E-GEOD-20499, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, E-TABM-321, E-GEOD-1153, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-19018, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-118, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-426, E-TABM-84

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-2487

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Processing time: 0.466 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM